The Effect of Anthocyanin Intake From Purple Sweet Potato in Cerebral Small Vessel Disease
Launched by INDONESIA UNIVERSITY · Apr 18, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is researching whether taking anthocyanins from purple sweet potatoes can help people with cerebral small vessel disease (CSVD). CSVD is a condition that affects the small blood vessels in the brain and can lead to issues like memory problems, difficulty walking, and even strokes. The study will compare the effects of purple sweet potato extract to a placebo (a treatment with no active ingredients) to see if it can improve blood flow in the brain and overall cognitive function.
To participate in this trial, you need to be between 40 and 65 years old and have been diagnosed with CSVD through an MRI scan. You should be able to walk on your own and have a good cognitive score. Participants will undergo tests to measure how well their blood vessels are functioning and how their thinking and movement skills are performing. It's important to note that some individuals, such as those with certain health conditions or who are intolerant to purple sweet potatoes, will not be eligible for this study. If you qualify and decide to join, you'll be contributing to important research that could lead to new ways to help people with CSVD.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CSVD patients aged 40-65 years.
- • CSVD patients have been diagnosed by MRI.
- • Willing to participate in the study and signed the consent letter after being given informed consent.
- • Have a Montreal Cognitive Assessment score of at least 26.
- • Able to walk independently with a motor score of at least 4, without proprioceptive disorders or neuropathy.
- Exclusion Criteria:
- • Closed temporal window on Transcranial Doppler examination
- • Acute phase of stroke
- • Hepatocellular injury
- • Chronic kidney disease
- • Intolerance to purple sweet potato
- • Aphasia
- • Neglected
- • Visual impairment.
- • Undergoing treatment with hormone replacement therapy (HRT), and corticosteroids.
About Indonesia University
Indonesia University is a leading academic institution dedicated to advancing healthcare through rigorous clinical research. As a trial sponsor, the university leverages its extensive expertise in medical science and collaboration with top-tier researchers to design and implement innovative clinical trials. Committed to ethical standards and patient safety, Indonesia University aims to contribute to the global body of knowledge in medicine, enhance therapeutic options, and improve health outcomes for diverse populations. Through its comprehensive approach, the university fosters an environment of scientific inquiry and collaboration, driving progress in clinical research and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Taufik Mesiano, MD
Principal Investigator
Doctoral Program in Medical Sciences Faculty of Medicine Universitas Indonesia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported